Metformin has different mechanisms that targets the splicing machinery in DM1: via AMPK-dependent and independent pathways and through the downregulation of RBM3 RNA-binding protein and could be in part defined by the overlap between the targets of RBM3 and those of MBNL1 [117]. This evidence concerns the gene RBM3 and myotonic dystrophy type 1.